An experimental sleeping pill from US drug company Merck is effective at helping people fall and stay asleep, according to reviewers at the US Food and Drug Administration, which could soon approve the new drug.
Federal health regulators say an experimental insomnia drug from Merck can help patients fall asleep, but it also carries worrisome side effects, including daytime drowsiness and suicidal thinking.
(AP)—Higher prices for its multiple sclerosis drug Rebif helped German pharmaceutical and high-tech materials company Merck KGaA post a 54 percent rise in first-quarter profit.
Two multinational drugmakers are teaming up with top global health groups to protect millions of girls in the world's poorest countries from deadly cervical cancer.
Drugmaker Merck & Co. says the Food and Drug Administration is reviewing its second application to sell a new type of allergy treatment meant to gradually reduce allergic reactions over time, rather than just relieving sneezing, ...
(HealthDay)—A genetic variant associated with weight loss after Roux-en-Y gastric bypass (RYGB) surgery has been identified, according to a study published in the May 2 issue of the American Journal of ...
Drugmaker Merck & Co. is reporting lower first-quarter results and cutting its 2013 profit forecast by 15 cents a share. It also is announcing a huge share buyback, up to $15 billion worth of its stock.
(HealthDay)—A new class of sleep medications appears to help people fall asleep without causing grogginess the next day, researchers say.
The U.S. Food and Drug Administration is looking into new evidence that suggests a group of recently approved diabetes drugs can increase the risk of pancreatitis and other problems.
(HealthDay)—For patients with preexisting occlusive vascular disease, the combination of niacin and the anti-flushing agent laropiprant provides no benefit and is associated with an increase in serious ...
A combination drug containing niacin failed to lower the risk of heart attacks or strokes and even proved harmful for some with vascular disease, a study released Saturday reported.
Merck KGaA saw its profit more than double in the fourth quarter as the German pharmaceutical company benefited from higher prices for its Rebif multiple sclerosis drug and reaped rewards from its ongoing restructuring.
Merck & Co.'s fourth-quarter profit fell 7 percent because of hits from generic competition and one-time charges, and the company pushed back plans to seek approval of a key experimental osteoporosis drug.
(HealthDay)—The drug Oxytrol has been approved by the U.S. Food and Drug Administration as the first over-the-counter treatment for women 18 and older with overactive bladder.
(HealthDay)—The cervical cancer vaccine has turned into one of the biggest success stories in the field.